Clinical Trial

Efficacy and Safety of Anti-PD-1/PD-L1 Treatment +/- UV1 Vaccination in Patients With Non-small Cell Lung Cancer

Study acronym: LUNGVAC
Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated November 9, 2023 (before its estimated July 1, 2025 completion). Its status may not reflect the trial's current state.
Summary
A Randomized, Multicenter Study Investigating Efficacy and Safety of anti-PD-1/PD-L1-treatment +/- UV1 vaccination as first line treatment in patients with inoperable advanced or metastatic non-small cell lung cancer. The objective of the phase 2 study is to induce a meaningful Progression-Free Survival (PFS) benefit in patients with stage IIIB/IIIC or stage IV NSCLC by treating with anti-PD-1/PD-L1 treatment and UV1 vaccination versus anti-PD-1/PD-L1 treatment alone.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2022-04-19; most recent amendment 2023-11-08.
Status change: Not Yet Recruiting → Recruiting 2022-08-15
Trial Details
NCT Number NCT05344209
Lead Sponsor Vestre Viken Hospital Trust
Collaborators: University Hospital, Akershus, Oslo University Hospital, Haukeland University Hospital, Helse Stavanger HF, Helse Fonna, Helse Nord-Trøndelag HF, St. Olavs Hospital, Alesund Hospital, Helse Forde, University Hospital of North Norway
Conditions Oncology, NSCLC Stage IV, NSCLC, Stage III
Enrollment 138 participants
Start Date 2022-08-12
Primary Completion 2025-07-01 (estimated)
Study Completion 2027-07-01 (estimated)
Updated on ClinicalTrials.gov 2023-11-09